Aptose Biosciences (APS.TO) on Thursday announced the publication of preclinical data for its lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR).
The paper is the first preclinical profiling of tuspetinib, a once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML).
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib with two other medications. Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or with one other medication have been completed.
"The non-clinical findings presented in the publication suggest that TUS will demonstrate favorable safety and a breadth of antileukemic activity across AML patient populations with a diversity of adverse mutations, and the initial clinical data is bearing that out," said CEO William Rice.
The company's shares were last seen up $0.01 to $0.27 on the Toronto Stock Exchange.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。